5YI9
Solution structure of the LEDGF/p75 IBD - JPO2 (aa 56-91) complex
5YI9 の概要
エントリーDOI | 10.2210/pdb5yi9/pdb |
分子名称 | PC4 and SFRS1-interacting protein,Cell division cycle-associated 7-like protein (1 entity in total) |
機能のキーワード | protein-protein complex, epigenetics, leukemia, transcription |
由来する生物種 | Homo sapiens (Human) 詳細 |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 16338.52 |
構造登録者 | |
主引用文献 | Sharma, S.,Cermakova, K.,De Rijck, J.,Demeulemeester, J.,Fabry, M.,El Ashkar, S.,Van Belle, S.,Lepsik, M.,Tesina, P.,Duchoslav, V.,Novak, P.,Hubalek, M.,Srb, P.,Christ, F.,Rezacova, P.,Hodges, H.C.,Debyser, Z.,Veverka, V. Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proc. Natl. Acad. Sci. U.S.A., 115:E7053-E7062, 2018 Cited by PubMed Abstract: Lens epithelium-derived growth factor/p75 (LEDGF/p75, or PSIP1) is a transcriptional coactivator that tethers other proteins to gene bodies. The chromatin tethering function of LEDGF/p75 is hijacked by HIV integrase to ensure viral integration at sites of active transcription. LEDGF/p75 is also important for the development of mixed-lineage leukemia (MLL), where it tethers the MLL1 fusion complex at aberrant MLL targets, inducing malignant transformation. However, little is known about how the LEDGF/p75 protein interaction network is regulated. Here, we obtained solution structures of the complete interfaces between the LEDGF/p75 integrase binding domain (IBD) and its cellular binding partners and validated another binding partner, Mediator subunit 1 (MED1). We reveal that structurally conserved IBD-binding motifs (IBMs) on known LEDGF/p75 binding partners can be regulated by phosphorylation, permitting switching between low- and high-affinity states. Finally, we show that elimination of IBM phosphorylation sites on MLL1 disrupts the oncogenic potential of primary MLL1-rearranged leukemic cells. Our results demonstrate that kinase-dependent phosphorylation of MLL1 represents a previously unknown oncogenic dependency that may be harnessed in the treatment of MLL-rearranged leukemia. PubMed: 29997176DOI: 10.1073/pnas.1803909115 主引用文献が同じPDBエントリー |
実験手法 | SOLUTION NMR |
構造検証レポート
検証レポート(詳細版)をダウンロード